Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
Martin Hutchings(University of Copenhagen), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Martine E.D. Chamuleau(Dutch Cancer Society), Kim Linton(The Christie NHS Foundation Trust), Rogier Mous(University Medical Center Utrecht), Kuo-mei Chen(Genmab (United States)), Dena DeMarco(Genmab (United States)), David Cunningham(Royal Marsden NHS Foundation Trust), Roberto S Oliveri(Genmab (Denmark)), Brian Elliott(Genmab (United States)), Anna Sureda(Institut Català d'Oncologia), Michael Roost Clausen(Vejle Sygehus), David Lewis(University Hospitals Plymouth NHS Trust), Peter Johnson(University of California, San Francisco)
Cited by 64
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Oesophageal cancer
|Nature Reviews Disease Primers|2017|1.1k